Shares in Acadia Pharmaceuticals experienced a significant surge, climbing 14% in extended trading following an announcement regarding its lead drug candidate in Europe. The European Medicines Agency (EMA) has accepted the resubmission of Acadia's marketing authorisation application for pimavanserin, a treatment specifically developed for Parkinson's disease psychosis.
This development marks a crucial step for Acadia, as it signifies renewed progress in bringing the drug to the European market. Pimavanserin is already approved and successfully marketed in the United States under the brand name Nuplazid, where it has been available since 2016. The drug aims to address hallucinations and delusions experienced by patients with Parkinson's disease, a common and debilitating symptom that significantly impacts quality of life.
The initial application for European approval was withdrawn by Acadia in 2020 after the EMA indicated that the data provided might not be sufficient to support approval without further studies. The resubmission suggests that Acadia has addressed the regulatory body's concerns, potentially with additional data or a revised dossier, paving the way for a fresh review process.
For Acadia, securing European approval would unlock a substantial new revenue stream and expand its global footprint beyond the US market. The European Union represents a significant patient population for Parkinson's disease, and consequently, a considerable market opportunity for effective treatments for associated conditions like psychosis. Investors are clearly reacting positively to the increased likelihood of market expansion, reflected in the sharp rise in share price.
While Acadia Pharmaceuticals is a US-based company, positive developments in major pharmaceutical firms can indirectly influence broader market sentiment, including among UK investors with diversified portfolios. UK-based institutional investors or individuals holding shares in global pharmaceutical exchange-traded funds (ETFs) or directly in Acadia could see an impact on their holdings. However, the direct impact on the FTSE 100 or UK household finances remains largely limited, given Acadia's primary listing outside the UK.